Study: NCT02201316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference mosapride citrate (GASMOTIN)
Description: Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 1)
Description: GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR107719B (Formulation 2)
Description: GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.